Opportunity Information: Apply for PAR 13 026
Apply for PAR 13 026
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Selected Topics in Transfusion Medicine (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Nov 23, 2012 and posted on Nov 23, 2012.
- Applicants must submit their applications by Jan 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts City or township governments Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities County governments State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Selected Topics in Transfusion Medicine (R01) opportunity (Funding Opportunity Number PAR-13-026) was a discretionary NIH research grant announcement from the National Heart, Lung, and Blood Institute (NHLBI) focused on strengthening blood banking and transfusion medicine through investigator-initiated research. Its main public health goal was to improve both the safety and the availability of the blood supply, while also advancing how transfusion medicine is practiced in real clinical settings. The FOA emphasized that transfusion medicine is not only about producing blood components, but also about protecting donors, ensuring product quality and availability, and reducing patient harm related to transfusion.
A central theme of the announcement was improving blood donor health and reducing risks tied to the donation process. This includes research aimed at understanding and preventing donation-related adverse events, identifying factors that make certain donors more vulnerable to complications, and designing approaches that keep donation as safe as possible across diverse populations. In parallel, the FOA prioritized work that strengthens the safety and availability of blood products themselves, encouraging studies that can improve how blood is collected, processed, stored, and managed so that patients have reliable access to safe products when they are needed.
The FOA also highlighted the importance of improving transfusion practice, with particular attention to transfusion-associated adverse events. It encouraged projects that better define the causes and determinants of transfusion complications and that develop evidence-based strategies to prevent, mitigate, or manage those risks. In practical terms, this could involve clinical, epidemiologic, translational, or systems-focused research intended to reduce preventable harm and support safer decision-making around transfusion.
Another major need identified in the announcement was maintaining an adequate blood supply over time. Beyond technical improvements, NHLBI called for research on donor recruitment and retention, including enhanced programs and strategies to encourage repeat donation and sustain participation. The FOA framed this as a critical component of national preparedness and routine health care delivery, since shortages or instability in supply can quickly become a patient safety issue.
From an administrative standpoint, this was an R01 research project grant under the NIH umbrella (CFDA 93.839, Blood Diseases and Resources Research). It did not require cost sharing or matching. The program was posted on November 23, 2012, and ultimately closed to new submissions on January 7, 2017, with an archive date of February 7, 2017. Eligibility was broad and included many types of U.S. and non-U.S. organizations, such as public and private institutions of higher education, nonprofit and for-profit entities (including small businesses), various local, county, state, tribal, and territorial governments, and a range of mission-focused institutions (for example HBCUs, Hispanic-serving institutions, and tribally controlled colleges and universities). Importantly, foreign organizations and foreign components were allowed under NIH policy, meaning international applicants and collaborations were explicitly within scope.
Overall, PAR-13-026 supported rigorous research meant to make transfusion medicine safer for patients, safer for donors, and more resilient in terms of supply, with NHLBI using the R01 mechanism to encourage substantial, hypothesis-driven projects that could produce durable improvements in blood safety, blood availability, and transfusion outcomes.
Frequently Asked Questions (FAQs): Selected Topics in Transfusion Medicine (R01) - PAR-13-026
What is the Selected Topics in Transfusion Medicine (R01) opportunity (PAR-13-026)?
PAR-13-026 was a discretionary NIH research grant announcement from the National Heart, Lung, and Blood Institute (NHLBI). It used the NIH R01 mechanism to support investigator-initiated research intended to strengthen blood banking and transfusion medicine.
Which NIH institute sponsored this funding opportunity?
The opportunity was sponsored by the National Heart, Lung, and Blood Institute (NHLBI).
What was the main public health goal of this FOA?
The main goal was to improve both the safety and the availability of the blood supply, while also advancing transfusion medicine as practiced in real clinical settings.
What was the overall focus area of the funded research?
The FOA focused on strengthening blood banking and transfusion medicine, including donor protection, blood product quality and availability, and reducing patient harm related to transfusion.
Did the FOA view transfusion medicine as more than producing blood components?
Yes. It emphasized that transfusion medicine includes protecting donors, ensuring product quality and availability, and reducing transfusion-related patient harm, not just producing blood components.
What types of research related to blood donor health were encouraged?
The FOA encouraged research aimed at improving blood donor health and reducing risks tied to the donation process, including understanding and preventing donation-related adverse events and identifying factors that make certain donors more vulnerable to complications.
What are examples of donation-process risks the FOA wanted addressed?
Based on the description, the FOA sought work that would (1) understand and prevent donation-related adverse events, (2) identify vulnerability factors for donor complications, and (3) design approaches that keep donation as safe as possible across diverse populations.
Did the FOA prioritize improving the safety and availability of blood products?
Yes. It prioritized research to strengthen both safety and availability of blood products, including studies that can improve how blood is collected, processed, stored, and managed so patients have reliable access to safe products.
What stages of the blood product lifecycle were within scope?
The FOA description explicitly referenced improvements to collection, processing, storage, and management of blood products.
What did the FOA say about improving transfusion practice?
It highlighted the importance of improving transfusion practice, with particular attention to transfusion-associated adverse events, and encouraged research that supports safer decision-making around transfusion in real clinical settings.
What kinds of transfusion complications were a focus of the announcement?
The FOA emphasized transfusion-associated adverse events, including work to better define the causes and determinants of transfusion complications and to develop evidence-based strategies to prevent, mitigate, or manage those risks.
What research approaches were encouraged for studying transfusion practice and complications?
The FOA indicated that clinical, epidemiologic, translational, and systems-focused research approaches could be relevant, as long as they are aimed at reducing preventable harm and improving transfusion outcomes.
Was maintaining an adequate blood supply considered a major need?
Yes. The FOA identified maintaining an adequate blood supply over time as a major need and framed supply stability as a patient safety issue.
Did the FOA support research on donor recruitment and retention?
Yes. It called for research on donor recruitment and retention, including enhanced programs and strategies to encourage repeat donation and sustain participation.
Why did the FOA connect donor retention to preparedness and routine care?
The FOA framed a stable blood supply as critical to national preparedness and routine health care delivery, noting that shortages or instability can quickly become a patient safety issue.
What grant mechanism was used?
This opportunity used the NIH R01 research project grant mechanism.
What does it mean that this was an "investigator-initiated" research opportunity?
As described, it was intended to support investigator-initiated research, meaning applicants proposed their own rigorous research projects aligned with the FOA priorities in transfusion medicine.
Was cost sharing or matching required?
No. The opportunity did not require cost sharing or matching.
What is the CFDA number associated with this program?
The CFDA listing provided was 93.839, Blood Diseases and Resources Research.
When was the FOA posted?
The program was posted on November 23, 2012.
When did the FOA close to new submissions?
It closed to new submissions on January 7, 2017.
What was the archive date?
The archive date listed was February 7, 2017.
Is this funding opportunity still accepting applications?
No. Based on the provided dates, it closed to new submissions on January 7, 2017 and was archived on February 7, 2017.
Who was eligible to apply?
Eligibility was broad and included many types of U.S. and non-U.S. organizations, such as public and private institutions of higher education; nonprofit and for-profit entities (including small businesses); and various local, county, state, tribal, and territorial governments.
Were mission-focused and capacity-building institutions included in eligibility?
Yes. The description specifically referenced eligibility that included mission-focused institutions such as HBCUs, Hispanic-serving institutions, and tribally controlled colleges and universities.
Were foreign organizations or international collaborations allowed?
Yes. Foreign organizations and foreign components were allowed under NIH policy, meaning international applicants and collaborations were explicitly within scope.
What kinds of outcomes was PAR-13-026 intended to produce?
It supported research intended to make transfusion medicine safer for patients, safer for donors, and more resilient in terms of supply, producing durable improvements in blood safety, blood availability, and transfusion outcomes.
What did NHLBI want to encourage by using the R01 mechanism for this FOA?
The FOA framed the R01 mechanism as a way to encourage substantial, rigorous, hypothesis-driven projects capable of producing durable improvements in transfusion medicine.
Browse more opportunities from the same category: Health
Next opportunity: HIGHER EDUCATION PARTNERSHIPS TO SUPPORT THE US BURMA COMMITMENT TO DEMOCRACY, PEACE AND PROSPERITY under Existing Annual Program Statement APS OAA 12 000003
Previous opportunity: Selected Topics in Transfusion Medicine (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 026
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 026) also looked into and applied for these:
| Funding Opportunity |
|---|
| Health Workforce Research Center (HWRC) Program Apply for HRSA 13 185 Funding Number: HRSA 13 185 Agency: Health Resources and Services Administration Category: Health Funding Amount: $500,000 |
| Nurse Education, Practice, Quality and Retention (NEPQR) Program Interprofessional Collaborative Practice Apply for HRSA 13 188 Funding Number: HRSA 13 188 Agency: Health Resources and Services Administration Category: Health Funding Amount: $500,000 |
| HIV Early Intervention Services (EIS) Program Existing Geographic Service Areas (EISEGA) Apply for HRSA 13 168 Funding Number: HRSA 13 168 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Community Based Dental Partnership Program Apply for HRSA 13 170 Funding Number: HRSA 13 170 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Natural History and Prevention of Viral Hepatitis Among Alaska Natives Apply for RFA PS 13 001 Funding Number: RFA PS 13 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Advanced Nursing Education Program Apply for HRSA 13 186 Funding Number: HRSA 13 186 Agency: Health Resources and Services Administration Category: Health Funding Amount: $375,000 |
| Communication for Healthy Communities Apply for RFA 617 13 000001 Funding Number: RFA 617 13 000001 Agency: Uganda USAID Kampala Category: Health Funding Amount: $50,000,000 |
| Medical Home Implementation for Children with Special Health Care Needs Apply for HRSA 13 216 Funding Number: HRSA 13 216 Agency: Health Resources and Services Administration Category: Health Funding Amount: $800,031 |
| National Center on Health Care Transition for Youth with Special Health Care Needs Apply for HRSA 13 218 Funding Number: HRSA 13 218 Agency: Health Resources and Services Administration Category: Health Funding Amount: $436,160 |
| Coordinating Center for an Undiagnosed Diseases Network (UDN) (U01) Apply for RFA RM 12 020 Funding Number: RFA RM 12 020 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Evaluation of Multi omic Data in Understanding the Human Microbiomes Role in Health and Disease (U54) Apply for RFA RM 12 021 Funding Number: RFA RM 12 021 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Technology Development for High Throughput Structural Biology Research (R01) Apply for PAR 13 032 Funding Number: PAR 13 032 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Nurse Faculty Loan Program (NFLP) Apply for HRSA 13 189 Funding Number: HRSA 13 189 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Technology Development for Protein Modeling (R01) Apply for PAR 13 033 Funding Number: PAR 13 033 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Small Health Care Provider Quality Improvement Grant Program Apply for HRSA 13 159 Funding Number: HRSA 13 159 Agency: Health Resources and Services Administration Category: Health Funding Amount: $150,000 |
| Birth Defects Study To Evaluate Pregnancy exposureS (BD STEPS) Apply for RFA DD 13 003 Funding Number: RFA DD 13 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| New Methods for Understanding the Functional Role of Human DNA Sequence Variants in Complex Phenotypes (R01) Apply for RFA GM 14 006 Funding Number: RFA GM 14 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Area (SAC AA) East Chicago, Indiana Apply for HRSA 13 263 Funding Number: HRSA 13 263 Agency: Health Resources and Services Administration Category: Health Funding Amount: $783,114 |
| NIMHD Transdisciplinary Collaborative Centers for Research on Mens Health (U54) Apply for RFA MD 13 004 Funding Number: RFA MD 13 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Research Grant for Secondary Analysis (R21) Apply for PAR 13 035 Funding Number: PAR 13 035 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 026", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.